Antara Banerjee
Vice President, Discovery & Biology 92Bio, Inc
Seminars
Tuesday 23rd June 2026
Harnessing Innate Immune Cell Biology to Address the Rise of NK, Gamma-Delta, Macrophage & Multi-Lineage Engagers for Enhanced Anti-Tumor Responses
8:30 am
Join this workshop to explore how emerging innate immune cell engagers are reshaping the next generation of T-cell engager therapeutics and overcoming resistance, improving safety, and expanding potential in solid tumors.
- Identifying high-value innate immune targets, including NK activating and inhibitory receptors, and macrophage checkpoint pathways to overcome tumor immune suppression
- Evaluating the advantages and limitations of NK, Gamma-Delta, macrophage, and multi-lineage engagers compared to traditional T-cell engagers
- Exploring engineering considerations for multi-functional molecules, including avidity, geometry, immune synapse formation, and balancing potency with safety
- Discussing appropriate preclinical and translational models to evaluate innate immune engagement, including humanized systems and tumor microenvironment platforms
- Defining safety considerations and the minimum preclinical data package required to justify advancing NK, macrophage, or multi-lineage engagers into clinical development
Tuesday 23rd June 2026
Conditionally Activated T Cell Engagers: Improving Safety, Selectivity & Therapeutic Index Through Tumor-Localized Design
11:00 am
Join this workshop to navigate the engineering trade‑offs required to unlock the potential of costimulatory engagers in solid tumors.
- Identifying tumor types, antigen contexts, and safety-limited targets where conditional activation can meaningfully expand the therapeutic window beyond conventional TCE formats
- Evaluating masking, protease-activated, pH/TME-responsive, and multi-layer conditional strategies across TCE architectures, including effects on efficacy, cytokine release, and durability of conditional control in vivo
- Designing robust tumor-localized activation mechanisms by optimizing linker choice, protease specificity, molecular stability, and responsiveness to heterogeneous tumor microenvironments
- Defining the mechanistic and pharmacological requirements for durable conditional control, including activation kinetics, dosing frequency, PD windows for T-cell killing, and risks of tumor adaptation
- Establishing the translational, clinical, and developability bar needed to justify conditional TCE complexity, from PK/exposure and biomarker strategies to trial design, manufacturability, regulatory expectations, and the extent of therapeutic index improvement
